MCID: MCL044
MIFTS: 21

Macular Degeneration, Age-Related, 9

Categories: Genetic diseases, Eye diseases, Rare diseases

Aliases & Classifications for Macular Degeneration, Age-Related, 9

MalaCards integrated aliases for Macular Degeneration, Age-Related, 9:

Name: Macular Degeneration, Age-Related, 9 54 71 13 69
Armd9 12 24 71
Age-Related Macular Degeneration 9 24 29
Age Related Macular Degeneration 9 12

Classifications:



External Ids:

OMIM 54 611378
Disease Ontology 12 DOID:0110021
MedGen 40 C1969651
MeSH 42 D008268

Summaries for Macular Degeneration, Age-Related, 9

UniProtKB/Swiss-Prot : 71 Macular degeneration, age-related, 9: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

MalaCards based summary : Macular Degeneration, Age-Related, 9, is also known as armd9. An important gene associated with Macular Degeneration, Age-Related, 9 is C3 (Complement C3). The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye and endothelial.

Disease Ontology : 12 An age related macular degeneration conferred by variation in the C3 gene on chromosome 19p13.

Description from OMIM: 611378

Related Diseases for Macular Degeneration, Age-Related, 9

Symptoms & Phenotypes for Macular Degeneration, Age-Related, 9

Clinical features from OMIM:

611378

Drugs & Therapeutics for Macular Degeneration, Age-Related, 9

Drugs for Macular Degeneration, Age-Related, 9 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
4 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
5 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
6 Endothelial Growth Factors Phase 4,Phase 2,Phase 3
7 Mitogens Phase 4,Phase 2,Phase 3
8 Antiemetics Phase 4,Phase 3,Phase 2
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
11 Autonomic Agents Phase 4,Phase 3,Phase 2
12 BB 1101 Phase 4,Phase 3,Phase 2
13 Dexamethasone acetate Phase 4,Phase 3,Phase 2 1177-87-3
14 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
15 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
16 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
18 Hormones Phase 4,Phase 3,Phase 2,Phase 1
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
21
protease inhibitors Phase 4,Phase 3,Phase 2
22
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
23
Triamcinolone Approved, Vet_approved Phase 3,Phase 1 124-94-7 31307
24
Verteporfin Approved, Investigational Phase 3,Phase 1,Phase 2 129497-78-5
25 Anecortave Investigational Phase 3 10184-70-0
26 Cortisol succinate Phase 3
27 Hydrocortisone 17-butyrate 21-propionate Phase 3
28 Hydrocortisone acetate Phase 3
29 Dermatologic Agents Phase 3,Phase 1,Phase 2
30 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
31 Photosensitizing Agents Phase 3,Phase 1,Phase 2
32 triamcinolone acetonide Phase 3,Phase 1
33 Triamcinolone diacetate Phase 3,Phase 1
34 Triamcinolone hexacetonide Phase 3,Phase 1
35 Pharmaceutical Solutions Phase 3,Phase 1
36 Anti-Bacterial Agents Phase 3,Phase 2
37 Ophthalmic Solutions Phase 3,Phase 1
38 Anti-Infective Agents Phase 3,Phase 2
39 Protective Agents Phase 3
40 Squalamine Phase 3
41
Acetazolamide Approved, Vet_approved Phase 2 59-66-5 1986
42
Fenofibrate Approved Phase 2 49562-28-9 3339
43
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
44
Everolimus Approved Phase 2 159351-69-6 6442177
45
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
46
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
47
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
48
Choline Approved, Nutraceutical Phase 2 62-49-7 305
49 Complement System Proteins Phase 2
50 Adrenergic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 55)

id Name Status NCT ID Phase Drugs
1 PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization Completed NCT00358345 Phase 4
2 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema Recruiting NCT02471651 Phase 4 Dexamethasone intravitreal implant (0.7 mg);Intravitreal anti-VEGF injection
3 TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration Unknown status NCT00260403 Phase 2, Phase 3
4 Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients Unknown status NCT02296567 Phase 2, Phase 3 Ranibizumab;Bevacizumab;Aflibercept;Ranibizumab;Bevacizumab;Aflibercept;Ranibizumab;Bevacizumab;Aflibercept
5 Systemic Avastin Therapy in Age-Related Macular Degeneration Completed NCT00531024 Phase 2, Phase 3 Bevacizumab;Sodium Chloride
6 Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD) Completed NCT00299507 Phase 3 Anecortave Acetate Sterile Suspension, 30 mg/mL;Anecortave Acetate Sterile Suspension, 60 mg/mL
7 A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Completed NCT00242580 Phase 3 Verteporfin photodynamic therapy;Pegaptanib;Triamcinolone acetonide
8 A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) Completed NCT00891735 Phase 3 Ranibizumab
9 A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Patients With Diabetic Macular Edema Recruiting NCT02121262 Phase 3 700 μg dexamethasone
10 Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD Active, not recruiting NCT02727881 Phase 3 Squalamine lactate ophthalmic solution, 0.2%;Placebo Ophthalmic solution;ranibizumab
11 Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis Suspended NCT00460967 Phase 3
12 Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase Terminated NCT02032173 Phase 3 Main group
13 Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System Unknown status NCT00100087 Phase 1, Phase 2
14 Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab Unknown status NCT01845844 Phase 1, Phase 2 Ranibizumab 0.3mg/0.05cc
15 Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT01162746 Phase 2 Intravitreal dexamethasone and intravitreal ranibizumab;Intravitreal ranibizumab
16 Lutein for Age-Related Macular Degeneration Completed NCT00006202 Phase 2 Lutein
17 Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) Completed NCT00935883 Phase 2 Eculizumab;Saline
18 Photodynamic and Pharmacologic Treatment of CNV Completed NCT00570193 Phase 1, Phase 2 verteporfin (Visudyne);ranibizumab (Lucentis)
19 Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab Completed NCT00804921 Phase 2 bevacizumab;acetazolamide;brimonidine
20 Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00284089 Phase 1, Phase 2 Ranibizumab
21 Lucentis for Inflammatory Macular Edema Trial Completed NCT00498355 Phase 1, Phase 2 Lucentis (ranibizumab)
22 Effect of Choline Fenofibrate (SLV348) on Macular Edema Completed NCT00683176 Phase 2 Choline Fenofibrate;Placebo
23 Ranibizumab and Bevacizumab for Diabetic Macular Edema Completed NCT01610557 Phase 2 Ranibizumab;Bevacizumab
24 Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab Completed NCT01292798 Phase 1, Phase 2 Ranibizumab
25 Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration Recruiting NCT02564978 Phase 2 Minocycline
26 Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration Recruiting NCT02286089 Phase 1, Phase 2
27 A Proof-of-Concept Study of RO6867461 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Active, not recruiting NCT02484690 Phase 2 RO6867461;Ranibizumab
28 Study of the Efficacy and Safety of the Ranibizumab Port Delivery System (RPDS) for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) (LADDER) Active, not recruiting NCT02510794 Phase 2 Ranibizumab
29 Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy Terminated NCT01675947 Phase 2 Sirolimus;Lidocaine
30 Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration Terminated NCT01577381 Phase 2
31 Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD) Completed NCT01301443 Phase 1 Subretinally injected RetinoStat
32 Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy Completed NCT00060749 Phase 1 Docosahexaenoic Acid (DHA) Dietary Supplement
33 Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60 Completed NCT00121589 Phase 1 Lutein
34 Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders Completed NCT00071227 Phase 1 Triamcinolone Acetonide (TAC-PF)
35 Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD Completed NCT02022540 Phase 1 PAN-90806 Ophthalmic Solution;Lucentis
36 Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X Completed NCT01869933 Phase 1 OC-10X
37 RGX-314 Gene Therapy for Neovascular AMD Trial Recruiting NCT03066258 Phase 1
38 Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) Active, not recruiting NCT01024998 Phase 1
39 Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye Unknown status NCT01348672
40 Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye Unknown status NCT01348633
41 A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life. Completed NCT00549055 Macugen
42 The Zeaxanthin and Visual Function Study Completed NCT00564902 3R 3'R Zeaxanthin
43 Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma? Completed NCT00312403
44 Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting Completed NCT01318941 Ranibizumab
45 Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema. Completed NCT02121197 Ozurdex
46 Major and Macular Branched Retinal Venous Occlusion Completed NCT01219205
47 Triamcinolone vs. Laser for Diabetic Macular Edema Completed NCT00229931 Triamcinolone acetonide
48 Diabetic Macular Edema Severity at Diagnosis Completed NCT00886392
49 Study of Dark Adaptation in Age-Related Macular Degeneration Recruiting NCT01352975
50 Deficits, Adaptation and Cerebral Functional Reorganization of Visual Retinotopic Treatments During Normal and Pathological Aging (Age-related Macular Degeneration and Glaucoma) Recruiting NCT03133117

Search NIH Clinical Center for Macular Degeneration, Age-Related, 9

Genetic Tests for Macular Degeneration, Age-Related, 9

Genetic tests related to Macular Degeneration, Age-Related, 9:

id Genetic test Affiliating Genes
1 Age-Related Macular Degeneration 9 29 24 C3

Anatomical Context for Macular Degeneration, Age-Related, 9

MalaCards organs/tissues related to Macular Degeneration, Age-Related, 9:

39
Eye, Endothelial

Publications for Macular Degeneration, Age-Related, 9

Variations for Macular Degeneration, Age-Related, 9

UniProtKB/Swiss-Prot genetic disease variations for Macular Degeneration, Age-Related, 9:

71
id Symbol AA change Variation ID SNP ID
1 C3 p.Lys155Gln VAR_070941 rs147859257

Expression for Macular Degeneration, Age-Related, 9

Search GEO for disease gene expression data for Macular Degeneration, Age-Related, 9.

Pathways for Macular Degeneration, Age-Related, 9

GO Terms for Macular Degeneration, Age-Related, 9

Sources for Macular Degeneration, Age-Related, 9

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....